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ABSTRACT
Context: Poliovirus (PV) receptor (CD155) is expressed on several kinds of cells and exerts diverse functions. Various investigations 
have confirmed that changes in CD155 expression in cancer cell lines affect metastasis, proliferation, and migration. 
Aims: The purpose of the present study was to investigate the CD155 transcript and protein expression in human colon adenocarcinoma 
cell lines in comparison to normal fetal human colon (FHC) cells. 
Materials and Methods: The CD155 expression level in four human adenocarcinoma cell lines and normal colon cell line were 
assessed using the SYBR green quantitative real‑time polymerase chain reaction (PCR) and flowcytometry.
Results: The results of real‑time PCR indicated that CD155 was significantly overexpressed in all human adenocarcinoma cell 
lines (P = 0.000). The highest and the lowest expression level of CD155 messenger RNA was observed in SW480 and HT29 cell 
lines by 491.14, and 12.04 fold changes, respectively, in comparison with the human normal cell line (FHC). Results of flowcytometry 
indicate that protein was strongly expressed in cancer cell lines. SW480 cells showed the highest CD155 protein expression level 
of 98.1%, whereas this protein expression was 1.3% in human normal colon cell line (FHC). Totally, these data indicate that CD155 
expression is significantly elevated in cancer cell lines. 
Conclusions: The preferential expression of CD155 on cancer cell lines rather than on normal cell line suggests that CD155 could 
be targeted for future PV virotherapy.
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INTRODUCTION
Colorectal cancer is the third leading frequent 
cancer in men and the second in women global.[1] 
Approximately 55% of the cases happen in developed 
countries.[2] There is a geographical variety in 
incidence worldwide, and the geographic models 
are very alike in males and females.[3] The various 
therapeutic approaches such as chemotherapy, 
surgery, and radiotherapy, employed separately 
or in various mixtures do not eliminate tumors or 
their progression all the time. Advanced molecular 
biomarkers for recruitment of new cancer virotherapy 
method are needed as treatment decisions should be 
based on cell‑based biological indicators.
The CD155 protein has been stated to be 
expressed in many kinds of cells with different 
functions[4,5] and was recognized as a receptor 
for polioviruses, which produces the typical 
flaccid paralysis of poliomyelitis[4,6] Studies have 
been shown the ubiquitous expression of CD155 
in several human tissues, containing the brain, 
liver, ileum, leukocytes, placenta, and lung.[4,7] 
CD155 is an immunoglobulin‑like molecule.[8] 
The amino‑terminal immunoglobulin region of 
the fundamental membrane graft alternatives of 
CD155 works as the poliovirus (PV) required moiety. 
Receptor coupling results in virion destabilization 
and cells.[9‑13] Selective targeting by PV is most 
likely determined by the distribution of its cellular 
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receptor, the Ig superfamily molecule CD155.[14] CD155 were 
stated to be included in cell–cell adhesion by a heterophilic 
through nectin‑3. The stimulation of this receptor was shown 
to repress cell adhesion and become cell movement,[15,16] while 
the loss of CD155 is leading to the inhibition of migration 
and induction of cell spreading. Cross‑linking of CD155 
and extracellular matrix have led to reduced adhesion to 
fibronectin, a reduction in some focal adhesions, and a rise in 
migration.[17] Overexpression of CD155 in cancer cells in the 
absence of ligand probably derives dimerization of CD155 
and results in reduced adhesion and raised movement.[16] 
Downregulation of CD155 in cancer cell lines reduces their 
movement,[16,18] proliferation,[19] and metastasis.[20] Earlier 
investigations have determined that representation of CD155 
be practically undetectable in nontransformed healthy cells. It 
can be attributable to the evidence that the promoter for the 
receptor is sufficient just over a limited period of growth.[21]
Higher expression level of CD155 in the sera of cases with 
breast, gynecologic, gastrointestinal, and lung cancers in 
comparison with sera of healthy donors has been reported. 
In addition, available evidence shows high expression level 
of CD155 in human cancer tissues.[22] It has been shown that 
CD155 was broadly expressed in several personal bones and 
soft‑tissue sarcoma cell groups.[14]
The objective of the present research is to represent the 
quantitative expression level of CD155 in four human colon 
adenocarcinoma cell lines and its normal counterpart in both 
messenger RNA (mRNA) and protein level using SYBR green 
real‑time polymerase chain reaction (PCR) and flowcytometer.
MATERIALS AND METHODS
Cell lines
Four human colon adenocarcinoma cell lines including 
HCT116 (C570), SW480 (C506), HT29 (C466), and Caco‑2 (C139) 
were obtained from National Cell Bank of Iran, and fetal human 
colon (FHC) (CRL‑1831) cell line was obtained from ATCC 
used in this study. The features of all colon adenocarcinoma 
cell lines are shown in Table 1.[23] The purpose of using four 
different cell lines is to investigate CD155 gene and protein 
expression level and its ability as potential cancer biomarker 
in cell lines with different stages of cancer from A to D. 
All cell culture mediums were supplemented through 10% 
heat‑inactivated fetal bovine serum (Gibco, Sigma‑Aldrich, 
Germany) and penicillin (100 units/ml), and streptomycin 
(0.1 mg/ml) (Gibco, Sigma‑Aldrich, Germany). The suitable 
medium for HCT116 and Caco‑2 Cell lines is Dulbecco’s 
modified eagle’s medium (DMEM): F12 and for SW480 and 
HT29 cell lines are RPMI 1640 containing sodium bicarbonate 
and L‑glutamine (Gibco, Germany). An additional 10 mM HEPES 
(for a final conc. of 24 mM), 10 ng/ml cholera toxin, 0.005 mg/ml 
transferrin, 0.005 mg/ml insulin, and 100 ng/ml hydrocortisone 
were added to FHC cell culture medium (DMEM: F12). All cells 
were grown at 37°C under humidified 5% CO
2
 atmosphere. 
Cancer cell lines are passaged twice a week. However, 
the normal cell line (FHC) was passaged once per 14 days 
(because of slow doubling time).
Extraction of total RNA and SYBR green real‑time polymerase 
chain reaction
Total RNA was extracted from 3 × 106 of each cell lines 
according to the TRI Reagent (Sigma‑Aldrich, Germany) 
protocol, and reverse transcriptase (RT) was done with Revert 
Aid First Strand complementary DNA Synthesis Kit from Thermo 
Scientific (Lithuania) using 4 μg of RNA as template and 1 μl 
of random hexamer primer in a reaction volume of 12 ml. The 
mixture was heated to 65°C for 5 min and then allowed to cool 
on ice. Four microliters of 5x reaction buffer, 2 μl of 10 mM 
dNTP mix, 1 μl of RT Revert Aid M‑MuLV RT (200 U/μl), and 1 
μl of Ribo Lock RNase Inhibitor (20 U/μL) were added and the 
reaction incubated for 5 min at 25°C followed by 60 min at 42°C. 
The reaction was stopped by heating at 70°C for 5 min and the 
RT stocks frozen at −80°C. SYBR green real‑time quantitative 
PCR analysis was carried out using an ABI Prism 7300 sequence 
detector system (Applied Biosystems, USA). The SYBR green 
real‑time quantitative PCR condition was as follows: add 4 μg 
of RT stock and mixed with 12.5 μl of RealQ Plus 2x Master 
Mix Green (High Rox) Ampliqon (Denmark), 0.2 pmol of each 
primer and water to a total volume of 25 μl. Beta‑actin gene was 
used as an endogenous housekeeping gene for normalization. 
All primer sets were listed in Table 2[24] and purchased from 
Bioneer (South Korea). The primers used to quantify expression 
of CD155 gene were located in a region corresponding to the 
extracellular domain of the protein, which is conserved in all 
spliced variants. Real‑time quantitative PCR Cycling conditions 
were as follows: an initial step at 95°C for 15 min, followed by 
forty cycles of 95°C for 15 s, and 60°C for 30 s. All assays were 
performed in triplicate and repeated three times.
Detection of CD155 protein expression in adenocarcinoma 
and normal human colon cell lines by flowcytometry
All  ce l l  l ines  were trypsinized,  and counted as 
5–10 × 105 cells/tube was suitable for flowcytometry analysis. 
Table 1: Features of four different colon adenocarcinoma 
cell lines studied
Cell line Patient Organ Stage
Caco-2 72-year-old male Colon C
HCT116 48-year-old male Colon ascendens D
HT29 44-year-old female Colon C
SW480 50-year-old male Colon B
Table 2: Primer sequences and their nucleotide binding site 
for expression of CD155 using real-time polymerase chain 
reaction
Primer name Sequence Nucleotide
Pol/F 5’-TGGACGGCAAGAATGTGACC-3’ 940–959
Pol/R 5’-ATCATAGCCAGAGATGGATACC-3’ 1055–1034
β-actin/F 5’-GTCTGCCTTGGTAGTGGATAATG-3’ 120–142
β-actin/R 5’-TCGAGGACGCCCTATCATGG-3’ 203–222
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The pellets were washed with 1 ml of phosphate‑buffered 
saline (PBS) and homogenized by pipetting. Each 500 μl of the 
cell suspension was placed in separate tube and centrifuged 
for 3 min at 664 xg. Supernatant was discarded, and pellets 
in the first tube were suspended in 300 μl cell staining buffer 
supplemented with 3 μl of phycoerythrin (PE) antihuman 
CD155 (PV receptor [PVR]) antibody (BioLegend, San Diego, 
CA, USA), and the second tube was suspended in 300 μl cell 
staining buffer supplemented with 3 μl of PE Mouse IgG2a, 
κ Isotype Control (BioLegend, San Diego, CA, USA). Tubes were 
incubated in dark chamber for 20 min. The cell suspension was 
washed twice with 1000 μl of PBS, centrifuged for 3 min at 
664 xg, and then cell pellets were suspended with 200 μl of 
PBS and analyzed by Flow Cytometer (BD Accuri C6).
Statistical analysis
Comparison of CD155 expression level on different human 
colon cancer and normal cell lines was analyzed by two‑way 
analysis of variance (post hoc) test. Statistical significance 
was determined to be P < 0.05. All statistical analyses were 
performed using SPSS.22 ( IBM SPSS Statistics V22.0, IBM United 
States Software).
RESULTS
Expression of CD155 mRNA is upregulated in human colorectal 
cancer cell lines than normal cell line.
Expression of the CD155 gene was significantly (P = 0.000) 
higher in all human colon cancer cell lines compared with 
the normal cell line as illustrated in Table 3. Quantification of 
obtained signals in real‑time PCR indicated that there were a 
491.14, 461.44, 24.25, and 12.04 fold increases in CD155 mRNA 
expression in SW480, HCT116, HT29, and Caco‑2 cell lines, 
respectively, compared with normal cell line (FHC). Comparison 
Figure 1: Comparison of CD155 messenger RNA expression fold 
changes in four human adenocarcinoma cell clines and normal colon 
cell line (fetal human colon) using SYBR green real-time polymerase 
chain reaction. Bars represent the mean ± standard error of the mean. 
***Indicates P = 0.0001. Post hoc test is applied
chart of CD155 gene expression in colorectal cancer and 
normal cell line is shown in Figure 1. As it shown, the highest 
expression level of CD155 mRNA was observed in SW480 cell 
line by 491.14 fold changes, while the lowest expression was 
belonged to HT29 cell line by 12.04 fold changes in comparison 
with human normal FHC cell line.
L o g a r i t h m i c  f o l d  c h a n g e  a m o n g  h u m a n  c o l o n 
adenocarcinoma cell lines showed that SW480 cell line has 
the highest (2.69) expression of CD155 gene Log
10
 fold in 
comparison with three other human colon adenocarcinoma 
cell lines (P = 0.000). HCT116 was shown significantly 
the next highest (2.66) expression of CD155 gene log 
10‑fold (P = 0.000), and the lowest Log 10‑fold change 
in CD155 gene expression was significantly belong to 
Caco‑2 (1.38) (P = 0.026) and HT29 (1.08) (P = 0.009) cell 
lines, respectively [Figure 2].
CD155 protein expression level is higher on colon 
adenocarcinoma cell lines in comparison to normal cell line
To examine CD155 protein expression across four different 
human colon adenocarcinoma cell lines and a normal 
Table 3: Expression of CD155 in different adenocarcinoma 
and normal human colon cell lines using SYBR green 
real-time polymerase chain reaction
Cell 
lines
Normalized gene 
expression
Fold 
change
SD Log10 
of fold 
change
FHC 1.31 1 0 0
SW480 648.06 491.1432 0.056569 2.691208
HCT116 608.87 461.4402 0.070711 2.664115
Caco-2 32 24.25147 0 1.384738
HT29 15.88 12.04197 0.692965 1.080698
Normalized gene expression=2−ΔCT, Fold change=2−ΔΔCT. SD=Standard 
deviation, FHC=Fetal human colon
Figure 2: Comparison of log 10 of CD155 messenger RNA expression 
fold changes in four human adenocarcinoma cell clines and normal 
colon cell line (fetal human colon) using SYBR green real-time 
polymerase chain reaction. Bars represent the log 10 mean ± standard 
error of the mean. ***Indicates P = 0.0001, **Indicates P = 0.001, and 
*Indicates P = 0.0001 post hoc test is applied
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human colon cell line as a control, flowcytometry analysis 
has performed. CD155 was detected by PE antihuman PVR 
CD155 monoclonal antibody, and an extensive level of 
expression was observed in adenocarcinoma cell lines. CD155 
protein was expressed on 98.1%, 96.7%, 87.7%, and 57.9% 
of SW480, HCT116, HT29, and Caco‑2 cell lines, respectively, 
whereas the CD155 protein was expressed 1.3% in normal FHC 
cell line [Figure 3]. Collectively, these data indicate a frequently 
Figure 3: Flowcytometry analysis of CD155 protein in adenocarcinoma and normal human colon cell lines; (a) SW480 cell line, (b) HCT116 cell 
line, (c) HT29 cell line, (d) Caco‑2 cell line, and (e) fetal human colon cell line. In each case, the left panel shows the distribution of fluorescence 
from individual cells plotted as a dot plot; and the middle and right histogram panels show images obtained from phycoerythrin mouse IgG2a, 
κ isotype control using FL2-A channels background, and phycoerythrin antihuman poliovirus receptor CD155 monoclonal antibody, respectively. 
FSC: Forward scatter. SSC: Side scatter
d
c
b
a
e
Zhand, et al.: Analysis of poliovirus receptor, CD155 expression
65Journal of Cancer Research and Therapeutics - Volume 15 - Issue 1 - January-March 2019
elevated CD155 expression in the primary adenocarcinoma 
cell lines.
DISCUSSION
The immunoglobulin‑like surface molecule, CD155 
expression, is common in cell lines established from 
ectodermal/neuroectodermal tumors.[25] It has been stated for 
glial,[21,26,27] colorectal,[24] lung,[28] breast,[29] and hepatocellular 
carcinoma[30] cancers through the privilege of selected 
lymphoma cell lines.[31]
Overexpression of CD155 was reported in cultured breast cancer 
cell line using western blotting and immunohistochemistry, by 
our result, they have reported an upregulation of the CD155 
expression.[29]
Bioinformatics evaluation of the SAGE and EST library 
databases maintained through the Cancer Genome Anatomy 
Project (http://www.cgap.nci.nih.gov) using the unique 
identifier AACCACCCAG moreover promotes the idea that 
expression of the CD155 gene might be elevated in various 
cancer types containing brain, colon, kidney, lung, stomach, 
and pancreas.[16]
The results of this study revealed that CD155 gene 
overexpressed at both mRNA and protein stages in different 
colorectal cancer cell lines originated from different stages of 
cancer[23] (SW480, HCT116, HT29, and caco‑2) in comparison 
with the normal colon cell line (FHC). As previously reported 
the CD155 level is significantly higher in patients with gastric 
cancer than controls and also patients with advanced stages 
(Stages 3 and 4) disease possessed more expression level of 
CD155 than early‑stage disease.[22] Nakai et al. showed CD155 
plays a role in mediating pulmonary tumor cell invasion 
with clinical significance for prognosis of primary pulmonary 
adenocarcinoma outcome.[28] Moreover, Qu et al. suggested that 
the loss of CD155 expression might play a significant role in 
the immune escape of HCC cells, and therefore, CD155 might 
serve as a prognostic marker as well as a potential therapeutic 
target for HCC.[32] Therefore, the CD155 expression level might 
be potentially beneficial as a biomarker for cancer development 
and progress.[22]
In another hand, the CD155/PVR expression level is 
determinant in the prediction of the viral therapy strategy 
result of colorectal cancer. Since here in the current research, 
we intended to investigate the different types of colorectal 
cancer cell lines originated from various tumor grades with 
different cellular characteristics. As of our knowledge, this is 
the first report on CD155 expression level in HT29, Caco‑2, 
and HTC116. The results of this study revealed that different 
colorectal cancer cell lines (SW480, HCT116, HT29, and Caco‑2) 
similarly express more CD155 at both protein and mRNA 
levels in comparison with the normal colon cell line (FHC). In 
accordance with our results, Zhang et al. reported the CD155 
protein upregulation in 3 colon cancer cells Colo205, SW480, 
and SW116 likewise the colon carcinoma tissues. However, 
they used the normal colon tissue as a reference instead of the 
normal colon cell line, FHC, which utilized in the current study. 
As we have shown that CD155 is expressed in 98.4% of the 
SW480 colon adenocarcinoma cells, they have also reported the 
approximately same rate of 95.1% for SW480 cells.[33] Priority 
of our data is based on the detection of CD155 transcript 
mRNA expression as well as the determination of protein 
expression level.
Our findings showed the upregulation of CD155 at both 
transcription and translation level in colorectal cancer cells, 
suggesting that upregulation of the CD155 starts from gene 
transcription process. It was stated and confirmed that CD155 
is linked through more advanced stages of HCC,[33] gastric[22] 
and pulmonary tumors,[28] indicating its value as a potential 
prognostic marker. In addition, there is no evidence supporting 
its association in highly advanced colorectal cancer tumors; 
our data showed that CD155 mRNA is mostly expressed in 
SW480 cell line which is originated from Grade 3–4 primary 
tumor, while the minimum CD155 expression observed in 
HT29 cells derived from Grade 1 tumor. Concordantly, it has 
been reported that CD155 representation is linked with the 
tumor stage with more expression in advanced metastatic 
tumors.[34]
Both et al. has  compared the migration and invasion capacity 
of different colorectal cancer cells (including SW480, HT29, and 
Caco‑2) with Matrigel assay, as their report SW480 acquires the 
most migration ability (58.3%), while Caco‑2 cells represent 
less migration score (4.4%).[35] Regarding the CD155 function 
in cell adhesion and migration enhancement, it is reasonable 
to compare the CD155 expression level with the migration 
capacity of these cells. Interestingly, the highly migratory 
SW480 cells have the highest level of CD155 among the 
studied colorectal cancer cells in the current study, as well as 
the Caco‑2 colorectal cancer cell line expressing less migration 
and invasion ability and concordantly the minimum CD155 
expression.[35]
Of notice, the HCT116 which is known as more enriched for 
cancer stem cell and high clonogenic features[36] possess the 
high expression of CD155 mRNA and protein in comparison 
to the well‑differentiated Caco‑2 cell line. Indeed, there is 
evidence supporting the function of alpha V integrin,[37] 
the associated concomitant of CD155 in cell adhesions in 
clonogenicity and self‑renewal regulation of cancer cells. It may 
suggest a potential role for CD155 in clonogenicity regulation, 
but more investigation is needed.
Altogether these finding supports the upregulation of CD155 
in colorectal cancer cells (SW480, HCT116, HT29, and Caco‑2). 
However, the cellular characteristics including the original 
tumor grade, the migratory capacity of the cell and the 
invasion potential have to be considered.
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Our finding suggested that detection of CD155 overexpression 
in human colon adenocarcinoma cell lines rather than normal 
cell line may hold promise for using this receptor for PV 
virotherapy candidate. Since our team is still working on this 
project (data not published), further fundamental studies are 
needed to clarify.
CONCLUSION
The overexpression of CD155 was recognized in all 4 Human 
adenocarcinoma cell lines. However, the magnitude of 
overexpression was different according to the type of cell 
lines. These results indicate that the selective overexpression 
of CD155 in cancer cell lines compare to normal cell line may 
more support the idea of CD155 targeted therapy of colon 
cancer by PV. Furthermore, our finding suggests that it is 
crucial to measure the level of CD155 overexpression in target 
cancer cells before PV virotherapy strategy.
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